Table 4.

Predicted Change in Number of Event Counts with the ASCVD Guidelines by Intensity of statin therapy in the MESA cohort accounting for actual statin use during the follow up. Assuming similar adherence rate as reported in clinical trials over 10 years.

	ASCVD(95% PI)*	NNT	Diabetes Mellitus(95% PI)*	NNH
NCEP/ATP III	N=1334, #Event=144		N=736, # Event=101
Moderate Intensity	−42.2(−57.3, −23.1)	31.7	7.8(1.0,14.2)	94.2
High Intensity	−55.4(−71.7,−36.8)	24.1	22.0(4.9,38.8)	33.5
	−13.2		14.2
New ACC/AHA	N=3015, # Event =269		N=2353, # Event =285
Moderate Intensity	−77.2(−104.2,−42.7)	39.1	22.2(2.8, 40.6)	106.2
High Intensity	−100.7(−129.4,−67.5)	29.9	63.0(14.0, 112.5)	37.4
	−23.6		40.6
Newly Eligible	N=1742, # Event=127		N= 1678, #Event =194
Moderate Intensity	−35.8(−48.1, −20.0)	48.7	15.2(1.9, 27.9)	110.7
High Intensity	−46.5(−59.4, −31.4)	37.45	43.4(9.6, 78.4)	38.6
Difference	−10.7		28.3

Note: 575 of the subcohort eligible under NCEP/ATP III and new ACC/AHA had diabetes mellitus; 23, 87 and 64 participants of the NCEP/ATP III, new ACC/AHA and newly eligible subcohorts had missing data on incident diabetes mellitus.

ASCVD: Indicates atherosclerotic cardiovascular disease, PI: Predicted interval, NNT: Number needed to treat, NNH: Number needed to harm

^*To obtain percent reduction in ASCVD events or T2DM caused = [(absolute number divided by #Event) × 100%]